Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Evotec Completes First Phase-I Study With EVT 401
Evotec has completed first phase-I study with P2X7 receptor antagonist, EVT 401. EVT 401 is a small molecule drug candidate and a potentially novel approach to orally treat
Evotec has completed first phase-I study with P2X7 receptor antagonist, EVT 401. EVT 401 is a small molecule drug candidate and a potentially novel approach to orally treat
MorphoSys would receive payment from Centocor Ortho Biotech in connection with the initiation of a phase-I clinical trial, using a HuCAL-derived, fully human antibody in the therapeutic area
YM BioSciences has reported that it’s subsidiary CIMYM BioSciences, and Oncoscience have resolved the issues between the companies. CIMYM has formally notified Oncoscience that it no longer intends
Biovest, a subsidiary of Accentia Biopharmaceuticals, has announced that BiovaxID, a personalized therapeutic anti-cancer vaccine, is available on a named-patient basis in Europe. A named-patient program is a
Takeda Global Research and Development Center has received a complete response letter from FDA, regarding the new drug application (NDA) for alogliptin. Its a selective dipeptidyl peptidase IV
Galderma’ Azzalure (botulinum toxin Type A), manufactured by Ipsen, has received marketing authorization in from the regulatory authorities in Germany. It is meant for the temporary improvement in
FDA has issued a notice of intent to Immucor to revoke its biologics license, with respect to its Reagent Red Blood Cells and Anti-E Blood Grouping Reagent product.
Radiant Research is enrolling subjects and establishing operational plans for upcoming H1N1 vaccine trials. Michael Kritschgau, Vice President of Radiant, said: “We have over a million subjects in
The Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on Gilead’s Marketing Authorisation Application for aztreonam lysine 75mg powder and solvent for nebuliser
Ortho Clinical Diagnostics (OCD) has opened a new manufacturing facility in Pencoed, Wales. The new, 110,000 square feet facility would employ over 350 people in manufacturing operations, quality,